
Zoetis Inc
NYSE:ZTS

US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
Retail
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
144.8514
196.0155
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
3M Co
NYSE:MMM
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.

Intrinsic Value
The intrinsic value of one
ZTS
stock under the Base Case scenario is
118.52
USD.
Compared to the current market price of 161.26 USD,
Zoetis Inc
is
Overvalued by 27%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Zoetis Inc
Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.

Valuation History
Historical valuation for ZTS cannot be conducted due to limitations such as insufficient data or other constraints.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:

A slowdown in global livestock production, especially in regions struggling with economic headwinds, could dampen demand for Zoetis' core farm-animal health products, limiting volume growth and pressuring margins.
Increasing competition from both established peers and emerging biosimilar developers could lead to pricing pressure on Zoetis’ premium pharmaceuticals and vaccines, siphoning off market share and eroding profitability.
Regulatory hurdles and frequent delays in new product approvals, particularly for novel therapeutics and genetics solutions, may inflate R&D expenses and slow the rollout of high-margin innovation in Zoetis’ pipeline.
Zoetis’ diverse global presence and balanced portfolio of both companion-animal and livestock products position it to benefit from rising pet ownership trends as well as continued demand for protein worldwide.
Strong relationships with veterinarians and breeders, alongside Zoetis’ targeted customer service and diagnostic offerings, create high switching costs and reinforce the company’s competitive moat in animal health solutions.
Accelerating innovation in genomic testing and digital technologies could unlock new revenue streams and deepen Zoetis’ customer engagement, fueling long-term organic growth through advanced, data-driven products and services.

Revenue & Expenses Breakdown
Zoetis Inc
Balance Sheet Decomposition
Zoetis Inc
Current Assets | 6B |
Cash & Short-Term Investments | 2B |
Receivables | 1.3B |
Other Current Assets | 2.7B |
Non-Current Assets | 8.3B |
PP&E | 3.6B |
Intangibles | 3.9B |
Other Non-Current Assets | 790m |
Current Liabilities | 3.4B |
Accounts Payable | 433m |
Accrued Liabilities | 1.2B |
Other Current Liabilities | 1.8B |
Non-Current Liabilities | 6.1B |
Long-Term Debt | 5.2B |
Other Non-Current Liabilities | 835m |
Free Cash Flow Analysis
Zoetis Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Zoetis Inc
Revenue
|
9.3B
USD
|
Cost of Revenue
|
-2.7B
USD
|
Gross Profit
|
6.5B
USD
|
Operating Expenses
|
-3.1B
USD
|
Operating Income
|
3.4B
USD
|
Other Expenses
|
-907m
USD
|
Net Income
|
2.5B
USD
|
ZTS Profitability Score
Profitability Due Diligence
Zoetis Inc's profitability score is 75/100. The higher the profitability score, the more profitable the company is.

Score
Zoetis Inc's profitability score is 75/100. The higher the profitability score, the more profitable the company is.
ZTS Solvency Score
Solvency Due Diligence
Zoetis Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Score
Zoetis Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ZTS Price Targets Summary
Zoetis Inc
According to Wall Street analysts, the average 1-year price target for
ZTS
is 209.99 USD
with a low forecast of 174.4 USD and a high forecast of 256.2 USD.
Dividends
Current shareholder yield for ZTS is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
ZTS
stock under the Base Case scenario is
118.52
USD.
Compared to the current market price of 161.26 USD,
Zoetis Inc
is
Overvalued by 27%.